retatrutide mechanism of action triple agonist glp-1 gip glucagon Retatrutide—A Game Changer in Obesity Pharmacotherapy Triple Agonism Based Therapies for

How Might GLP-1s Improve Pregnancy Outcomes

This compound has a half-life of approximately 57 days after s.c

Long-term bariatric surgery outcomes are consistently durable, with major societies noting sustained weight loss years after surgery

Moreover, a decrease in atherosclerotic cardiovascular disease (ASCVD) has been found in people treated with semaglutide who were obese or overweight, but, this trend was not statistically significant [28]

The TRIUMPH program enrolled more than 5,800 participants across multiple registrational trials evaluating retatrutide across obesity, obstructive sleep apnoea, and knee osteoarthritis comorbidities

IH has received grants from AstraZeneca/Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lexicon Pharmaceuticals, Medtronic, Merck & Co., Novo Nordisk, the Population Health Research Institute and Sanofi